CN101460490A - 取代的环稠合吖嗪类及其在癌症疗法中的应用 - Google Patents

取代的环稠合吖嗪类及其在癌症疗法中的应用 Download PDF

Info

Publication number
CN101460490A
CN101460490A CNA2007800204647A CN200780020464A CN101460490A CN 101460490 A CN101460490 A CN 101460490A CN A2007800204647 A CNA2007800204647 A CN A2007800204647A CN 200780020464 A CN200780020464 A CN 200780020464A CN 101460490 A CN101460490 A CN 101460490A
Authority
CN
China
Prior art keywords
cumarone
dimethyl
quinazolyl
propylene diamine
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800204647A
Other languages
English (en)
Chinese (zh)
Inventor
W·A·丹尼
B·C·巴格利
E·S·马歇尔
H·S·萨泽兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN101460490A publication Critical patent/CN101460490A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800204647A 2006-04-07 2007-04-04 取代的环稠合吖嗪类及其在癌症疗法中的应用 Pending CN101460490A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ546477A NZ546477A (en) 2006-04-07 2006-04-07 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
NZ546477 2006-04-07

Publications (1)

Publication Number Publication Date
CN101460490A true CN101460490A (zh) 2009-06-17

Family

ID=38581368

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800204647A Pending CN101460490A (zh) 2006-04-07 2007-04-04 取代的环稠合吖嗪类及其在癌症疗法中的应用

Country Status (8)

Country Link
US (1) US20090318479A1 (enExample)
EP (1) EP2004637A4 (enExample)
JP (1) JP2009533338A (enExample)
CN (1) CN101460490A (enExample)
AU (1) AU2007235751A1 (enExample)
CA (1) CA2648323A1 (enExample)
NZ (1) NZ546477A (enExample)
WO (1) WO2007117161A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107721982A (zh) * 2017-10-16 2018-02-23 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543A (zh) * 2020-01-03 2021-07-06 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
CN114044769A (zh) * 2021-11-25 2022-02-15 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN117247374A (zh) * 2022-06-10 2023-12-19 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制药用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
KR20150016406A (ko) 2012-06-07 2015-02-11 에프. 호프만-라 로슈 아게 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
MX2017005346A (es) * 2014-10-29 2017-08-02 Dong A St Co Ltd Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm).
US20170057955A1 (en) * 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
WO2021155426A1 (en) * 2020-02-04 2021-08-12 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer
WO2022061224A1 (en) 2020-09-21 2022-03-24 Landos Biopharma, Inc. Nlrx1 ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
EP1088818B1 (en) * 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107721982A (zh) * 2017-10-16 2018-02-23 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN107721982B (zh) * 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543A (zh) * 2020-01-03 2021-07-06 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
CN114044769A (zh) * 2021-11-25 2022-02-15 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN114044769B (zh) * 2021-11-25 2023-12-12 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN117247374A (zh) * 2022-06-10 2023-12-19 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制药用途

Also Published As

Publication number Publication date
CA2648323A1 (en) 2007-10-18
US20090318479A1 (en) 2009-12-24
NZ546477A (en) 2009-04-30
AU2007235751A1 (en) 2007-10-18
JP2009533338A (ja) 2009-09-17
EP2004637A1 (en) 2008-12-24
EP2004637A4 (en) 2010-11-03
WO2007117161A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CN101460490A (zh) 取代的环稠合吖嗪类及其在癌症疗法中的应用
JP3330706B2 (ja) キナゾリン誘導体、その製法及びこれを含有する抗癌作用を有する医薬組成物
EP1458394B1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3
ES2228522T3 (es) Pirazolbenzodiacepinas como inhibidores de cdk2.
WO2009077956A2 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Нh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
CZ288489B6 (en) Quinazoline derivatives, process of their preparation and pharmaceutical preparation, in which they are comprised
SK6172002A3 (en) Heterocyclic substituted pyrazolones
CN101415688A (zh) 具有b-raf抑制活性的喹唑啉酮衍生物
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
CN106349241B (zh) 具有hsp90抑制活性的三唑衍生物及其制备方法和应用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CA2540861A1 (en) Novel tetraydrospiro{piperidine-2,7' -pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-ht6 receptor -related disorders
BRPI0710293A2 (pt) n-(aril- ou heteroaril)-pirazol[1,5-a]pirimidinas 3-substituìdas como inibidores de cinase
EP1599202A1 (en) Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN107286174A (zh) 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
CN110655505B (zh) 6-(2-氨基-1H-苯并[d]咪唑-6-基)喹唑啉-4(3H)-酮类化合物
EP1228043B1 (en) Isoquinoline and quinazoline deivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
KR100397792B1 (ko) 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CN109970717B (zh) 4-(脂肪环并嘧啶/吡啶取代)氨基-1h-3-吡唑甲酰胺类flt3抑制剂及其用途
CN103382182A (zh) 苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
JP2001512734A (ja) ３−置換３，４，５，７−テトラヒドロピロロ［３’，４’：４，５］−チエノ［２，３−ｄ］ピリミジン誘導体、その製造方法および５ＨＴ拮抗薬としての使用
CN101115744A (zh) 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐
CN118652239A (zh) 一类egfr别构抑制剂的合成及其用途
AU2015222590B2 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
CN103626761B (zh) 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090617